The Elder Scrolls's lore is so complicated that picking out the most powerful characters can be difficult. However, we are ...
Jazz Pharmaceuticals has reached an agreement to buy Nasdaq-listed Chimerix for around $935 million, adding a brain cancer drug that is heading for an FDA verdict in the summer. The Irish and US ...
Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations, a rare brain cancer mainly affecting young people. The ...
"I sit here just knowing that my babies are a part of me on a cellular level and that healed something in me when I heard ...
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Hosted on MSN
Chimeric's AML trial hits 60% response as ASX dips
Chimeric Therapeutics reported a 60% complete response rate in its Phase 1b AML trial, far exceeding the 20–30% standard of care. The announcement came as the ASX opened lower amid geopolitical ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene ...
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an ...
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results